Wellnex Life Limited announced the formal appointment of three highly respected and experienced directors to the board of Wellnex. These appointments will provide invaluable and experience, guidance and increased corporate governance to Wellnex that will drive the Company in building sales and profitability in the growing healthcare and pharmaceutical markets. Mr. Tascone has a long history of success in the consumer health and wellness market, serving as Director of Sales and Marketing for Australia's leading pharmacy retailer, Chemist Warehouse.

The appointment of Mr. Tascone as Chair will provide invaluable expertise as they continue to grow brands, including the recently acquired leading topical pain relief brand, Pain Away. Wellnex has a close relationship with Chemist Warehouse, being Wellnex's 6th largest shareholder and the companies having two joint ventures together which will be further be strengthened following the appointment of Mr. Tascone as Chair. Mr. Tascone currently has no other ASX director roles.

Mr. Vidler has comprehensive experience across retail, consumer health products and retail pharmacy. Andrew's 30 years' experience includes approximately 20 years with the EBOS Group (formerly FH Faulding, Mayne Group and Symbion), where, across several roles, he led the Terry White Chemists and Chemmart pharmacy brands and the Endeavour Consumer Health products business. Mr. Vidler is currently Pacific Smiles Group's Managing Director and Chief Executive Officer.

Aside from this role, Mr. Vidler has no other ASX director roles. For the last four years Mr. Vidler worked for API Limited (now Wesfarmers Health) where he was responsible for the Priceline retail and Priceline pharmacy businesses. Mr. Vidler has a track record of building strong team cultures while ensuring they stay focused on the marketplace and building customers with an active preference for the products, brands and retailers he oversees.

Mr. Yeh is an experienced all-rounded entrepreneur, with over 21 years' experience in all aspects of pharmaceutical sales, marketing, production, quality assurance, operations, logistics, finance and management. Mr. Yeh co-founded Homart Pharmaceuticals (Homart) in 2002, and since then has grown Homart into a premier and award winning manufacturing and brand business with over 200 employees and an international presence. Homart, and it's related entities, currently have a 18.3% shareholding in the Company.

Mr. Yeh currently has no other ASX director roles.